60 results
8-K
EX-99.1
GLYC
GlycoMimetics Inc
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
costs due to the completion of engineering and validation batches for uproleselan, partially offset by the Phase 1 clinical trial of GMI-1687.
G … to $19.1 million in the prior year. The overall increase was due to higher personnel-related expenses, offset in part by a decrease in external
8-K
EX-99.1
GLYC
GlycoMimetics Inc
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
related to the Phase 1a trial of GMI-1687 in healthy adult volunteers, which was initiated in August 2023; the increase was partially offset
8-K
EX-10.1
cemwq8se mx
20 May 22
Departure of Directors or Certain Officers
1:09pm
8-K
EX-99.1
sgg70o9s4 pg4hc62
28 Apr 22
GlycoMimetics Reports Highlights and Financial Results
8:30am
8-K
EX-99.1
92we7xi2dfke6grs
3 Mar 22
GlycoMimetics Reports Highlights and Financial Results
8:45am
8-K
EX-99.1
a3xz 9taxmoflvw7a
2 Mar 21
Glycomimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2020
4:16pm